Skip to main content

Benitec Says USPTO Withdraws Novelty Objection Against Core Patent

Premium

Benitec announced this week that the US Patent and Trademark Office has withdrawn a novelty objection to the company's core US patent as part of an ongoing re-examination process of the intellectual property.

Claims within the patent, No. 6,573,099, however, have still been rejected based on objections related to the fundamental Fire and Mello patent held by the Carnegie Institute, according to Benitec. Overcoming these rejections, the company said, will likely require a review by the patent office's board of appeals.

Such a move will likely take around 12 months, Benitec added.

Benitec’s IP woes began in 2004 when it sued three companies for infringing the ‘099 patent, which essentially claims gene-expression knockdown using DNA that transcribes double-stranded RNA (see RNAi News, 4/2/2004). One of those companies, Nucleonics, fought the case in court and, as part of its legal strategy, either opposed the patent or requested re-examinations of Benitec’s IP in several nations, including the US.

Although the patent-infringement suit was ultimately withdrawn by Benitec and Nucleonics has since shut down its operations (see RNAi News, 11/6/2008), the re-examination proceeded.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.